Natera Inc (NTRA)

Currency in USD
275.40
+5.04(+1.86%)
Closed·
279.55+4.36(+1.59%)
·
NTRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
265.24276.97
52 wk Range
134.85288.04
Key Statistics
Prev. Close
270.36
Open
270.36
Day's Range
265.24-276.97
52 wk Range
134.85-288.04
Volume
1.69M
Average Volume (3m)
1.51M
1-Year Change
101.6548%
Book Value / Share
12.52
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NTRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
282.86
Upside
+2.71%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Natera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

19 Buy
3 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 282.86
(+2.71% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Buy300.00+8.93%-New Coverage30-07-2026
Canaccord
Buy330.00+19.83%285.00Maintain14-07-2026
Baird
Buy329.00+19.46%265.00Maintain13-07-2026
Morgan Stanley
Buy310.00+12.56%250.00Maintain09-07-2026
Guggenheim
Buy290.00+5.30%270.00Maintain29-06-2026

Natera Inc SWOT Analysis


Genetic Testing Giant
Natera's strong performance in genetic testing, particularly in oncology, drives impressive stock growth and optimistic revenue projections
Medicare Expansion
Potential Medicare coverage for additional cancer types could significantly boost Natera's addressable market and accelerate clinical adoption
Margin Momentum
Explore Natera's strategies for margin improvement, including price increases, cost reduction initiatives, and a shift towards more profitable tests
Analyst Optimism
With price targets around $120, analysts remain bullish on Natera's unique offerings and growth potential in the evolving personalized medicine landscape
Read full SWOT analysis

Natera Inc Earnings Call Summary for Q1/2026

  • Q1 2026 revenue hit $696.64M, up 39% YoY and beating forecast of $617.2M; EPS of -$0.60 missed estimate of -$0.54 by 11.11%
  • Stock dropped 9.69% to $194.24 in after-hours trading following earnings miss, with modest premarket recovery to $195
  • Gross margins improved to 64.8%, exceeding prior 64% guidance; full-year 2026 margin guidance raised to 65% at midpoint
  • New product Fetal Focus showed strong adoption; Signatera ASP growth continues with long-term target of $2,000 per test maintained
  • Key challenges include managing operating expenses for profitability, cash collection delays, and competitive pressures in biotech sector
Last Updated: 11-05-2026, 09:50 pm
Read Full Transcript

Earnings

Latest Release
07-05-2026
EPS / Forecast
-0.60 / -0.54
Revenue / Forecast
696.64M / 617.2M
EPS Revisions
Last 90 days

NTRA Income Statement

Compare NTRA to Peers and Sector

Metrics to compare
NTRA
Peers
Sector
Relationship
P/E Ratio
−171.1x−25.3x−0.4x
PEG Ratio
16.35−0.410.00
Price/Book
21.8x14.2x2.6x
Price / LTM Sales
15.5x3.3x3.0x
Upside (Analyst Target)
7.3%4.1%54.3%
Fair Value Upside
Unlock−3.2%8.4%Unlock

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
69.89M48.80%18.90B
Other Institutional Investors
69.53M48.55%18.80B
Public Companies & Retail Investors
3.79M2.65%1.03B
Total
143.22M100.00%38.72B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
T. Rowe Price Group, Inc.9.30%1,33,15,69636,00,032
JP Morgan Asset Management7.72%1,10,53,55429,88,439

FAQ

What Is the Natera Inc (NTRA) Share Price Today?

The Natera Inc share price today is 275.40.

What is the current Natera Inc (NTRA) share price and day range?

As of 04-08-2026, the Natera Inc share price is 275.40, with a previous close of 270.36. The share price has ranged from 265.24 to 276.97 today, while the 52-week range spans from 134.85 to 288.04.

What Is the Natera Inc Market Cap?

As of today, Natera Inc market cap is 38.72B.

What Is the Natera Inc (NTRA) Share Price Target?

The average 12-month share price target for Natera Inc is 282.86, with a high estimate of 330 and a low estimate of 193. 19 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +2.71% Upside potential.

What Is Natera Inc's Earnings Per Share (TTM)?

The Natera Inc EPS (TTM) is -1.64.

When Is the Next Natera Inc Earnings Date?

Natera Inc will release its next earnings report on 06-08-2026.

From a Technical Analysis Perspective, Is NTRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Natera Inc Trade On?

Natera Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Natera Inc?

The stock symbol for Natera Inc is "NTRA."

How Many Times Has Natera Inc Stock Split?

Natera Inc has split 0 times.

How Many Employees Does Natera Inc Have?

Natera Inc has 6138 employees.

What Is the NTRA Premarket Price?

NTRA's last pre-market stock price is 270.00. The pre-market share volume is 920.00, and the stock has changed by -0.36, or -0.13%.

What Is the NTRA After Hours Price?

NTRA's last after hours stock price is 279.55, the stock has changed by 4.36, or 1.59%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.